KBK. A. Blonsky

K. A. Blonsky

*This is an algorithmically generated author record based on publicly available information.

K. A. Blonsky has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and tolerability of co-administration of clozapine with atypical antipsychotics in patients with treatment-resistant schizophrenia, comorbid with chemical addictions

    by G.YU. Selivanov, N.A. Bokhan, T.V. Shushpanova, A.A. Salnikov, K.A. Blonsky, A.P. Otmakhov

    Objective. To compare the efficacy and tolerability of combination therapy with clozapine and atypical antipsychotics for patients with treatment-resistant schizophrenia, comorbid with chemical addictions. Material and methods. A clinical study was conducted from 2018 to 2026 in various psychiatric departments in the North-Western, Siberian, and Ural regions of the Russian Federation. The study included a total of 470 male and female participants diagnosed with therapeutically resistant paranoid schizophrenia, comprising individuals with and without concomitant chemical addictions: n=80 without addictions; n=390 with unrelated chemical addictions (opioid, cannabinoid, psychostimulant, and ethanol dependence). Participants were randomly allocated into six treatment groups receiving distinct combinations of medications: clozapine with cariprazine (n=84), lurasidone (n=84), aripiprazole (n=78), risperidone (n=84), olanzapine (n=70), or brexpiprazole (n=70). The clinical status of patients was assessed at weeks 2 and 6 of the therapeutic regimen. Results. A comparative analysis of treatment efficacy indicated significant differences between therapy groups across various psychometric scales (p<0.05). The co-administration of clozapine with cariprazine, and to a lesser extent with lurasidone, demonstrated the most pronounced therapeutic effect within a 42-day treatment period (p<0.05), specifically in alleviating psychotic symptoms and reducing the negative symptoms characteristic of schizophrenia, as compared to alternative combinations, thereby extending the duration of outpatient treatment. Conclusions. A comprehensive treatment strategy for therapeutically resistant schizophrenia, irrespective of concomitant addictions, is the combination of clozapine with cariprazine; lurasidone serves as an alternative option. The selection of an effective adjunctive therapy should consider the specific type of addiction: lurasidone or aripiprazole is recommended for cannabinoid, psychostimulant, and alcohol dependencies; risperidone or olanzapine is advised for opioid and alcohol dependencies. The combination with brexpiprazole is deemed ineffective. Notable advantages of this approach include a marked effect on negative symptoms and an extension of the outpatient treatment period. No adverse events associated with the combination therapy were reported.

  • Open Access

    Cariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions

    by G. Yu. Selivanov, N. A. Bokhan, A. P. Otmakhov, O. V. Semina, K. A. Blonsky, А. А. Сальников

    Background: endogenous psychoses complicated with different addictions have special psychopathological structure including delirious episodes, true hallucinations combined with typical positive symptoms of schizophrenia. These cases are difficult for treatment due to non-compliance of patients and their bad tolerance to drugs. The aim was to study the most effective psychopharmacological treatment using cariprazine for acute psychotic states in paranoid schizophrenia combined with chemical addictions. Patients and Methods: the study was conducted at psychiatric hospitals of Tomsk region, St. Petersburg, Nizhnevartovsk and Noyabrsk from 2018 to 2024. 208 men aged 18 to 45 years suffering from paranoid schizophrenia and dependent on psychoactive substances were examined. The main group made up 104 in-patients, who took cariprazine alone or in combination with haloperidol or chlorpromazine. The control group included 104 in-patients treated with other antipsychotics (aripiprazole, risperidone, olanzapine). Research methods: clinical and psychopathological, psychometric (PANSS, SANS, CGI, GAF), statistical (Python 3.11.0; R version 3.2.4; SPSS Statistics Base 22.0). Results: It was revealed that when comparing the control group with the main group, similar indicators were observed on the CGI and GAF scales on the 2nd week of the study, and on the 4th week of the study, compared with the control group, an improvement in indicators on the PANSS, SANS, CGI, GAF scales was observed. Conclusions: Cariprazine, compared with other atypical antipsychotics (risperidone, olanzapine, aripiprazole), showed a distinct antipsychotic effect in the treatment of acute psychotic states in patients with schizophrenia dependent on psychoactive substances. By the end of the 2nd week after hospitalization, when treating with cariprazine at an average dose of 3 to 6 mg/day in combination with typical neuroleptics (haloperidol, chlorpromazine) or a tranquilizer, the most pronounced antipsychotic effect is achieved. Subsequent isolated use of cariprazine at a therapeutic dose of 3–4.5 mg/day has an effect similar to that of leading atypical antipsychotics by the end of the 4th week of treatment. Unlike other atypical antipsychotics, cariprazine was more effective in the treatment of negative symptoms of schizophrenia, which made it possible to achieve an improvement in overall functioning, increase the duration of remission, and reduce the risk of rehospitalization and the development of hospitalism.


  • Open Access

    Mental Disorders Associated with the Abuse of Synthetic Cannabinoids (Spices)

    by N. A. Bokhan, G. Yu. Selivanov, А. А. Сальников, K. A. Blonsky

    Introduction: the abuse of synthetic cannabinoids may trigger the development of mental disorders characterized by distortions of disease processes that can cause incorrect diagnosis.Objective: to study the phenomenon of the abuse of synthetic cannabinoids (Spice) as a trigger psychotic episode in psychiatric patients (with schizophrenia and personality disorders) and risk factors for developing paranoid schizophrenia.Patients and research methods: 291 men were examined: 241 with dependence on synthetic cannabinoids — 101 of them were diagnosed with personality and behavior disorders in adulthood, 140 with a diagnosis of paranoid schizophrenia and 50 with a diagnosis of paranoid schizophrenia without drug dependence.Research methods: clinicalpsychopathological, psychometric (SANS, CGI, MMPI), follow-up, statistical R (R version 3.2.4).Results: intoxication conditions caused by synthetic cannabinoids can provoke the development of psychotic episodes and be a trigger for the manifestation of schizophrenia. There are four variants of narcotic intoxication: delirious, schizophrenic, with pseudo-hallucinations, with delirium. The personalities of patients addicted to synthetic cannabinoids are similar in the prevalence of emotionally unstable, rigid, introverted, deviant traits. Patients with personality disorders, dependent on synthetic cannabinoids, differed from typical drug addicts in such patterns of behavior as disorganization, conflict, unpredictability, spontaneity, thoughtlessness of actions, impulsivity, and nonconformity. The stigmatizing signs of the schizophrenic process in patients who are dependent on synthetic cannabinoids are the symptoms of abulia–apathy of mild severity. Patients with schizophrenia, dependent on synthetic cannabinoids, differed from patients without dependence on drugs by the phenomenon of the absence of an emotional defect expressed in the expressiveness of emotions, the desire for communication.Conclusion: the phenomenon of synthetic cannabinoid abuse is a trigger of a psychotic episode in both schizophrenic patients and those with personality disorders in whom antisocial, schizoid and paranoid personality traits prevail. The abuse of synthetic cannabinoids is a risk factor for the development of paranoid schizophrenia, which differs from schizophrenia without drug dependence by a mild degree of stigmatizing symptoms of abulia–apathy and social activity during periods of short-term remissions.